Table 3.
Association of adverse reactions with therapeutic regimens
| Adverse reaction, grade 2 | F-A (n=1,049), n (%) | F-B (n=235), n (%) | P-value | S-A (n=381), n (%) | S-B (n=129), n (%) | P-value | M-A (n=57), n (%) | M-B (n=19), n (%) | P-value |
|---|---|---|---|---|---|---|---|---|---|
| Hematological | |||||||||
| Neutropenia | 429 (40.9) | 66 (28.1) | <0.01 | 143 (37.5) | 40 (31.0) | >0.05 | 24 (42.1) | 8 (42.1) | >0.05 |
| Anemia | 125 (11.9) | 25 (10.6) | >0.05 | 41 (10.8) | 13 (10.0) | >0.05 | 6 (10.5) | 3 (15.8) | >0.05 |
| Thrombocytopenia | 251 (23.9) | 51 (21.7) | >0.05 | 81 (21.3%) | 26 (20.2) | >0.05 | 10 (17.5) | 3 (15.8) | >0.05 |
| Nonhematological | |||||||||
| Asthenia | 566 (54.0) | 108 (46.0) | 0.026 | 185 (48.6) | 53 (41.1) | >0.05 | 30 (52.6) | 11 (57.9) | >0.05 |
| Aorexia | 520 (49.6) | 115 (48.9) | >0.05 | 162 (42.5) | 54 (41.9) | >0.05 | 26 (45.6) | 8 (42.1) | >0.05 |
| Vomiting | 59 (5.6) | 14 (6.0) | >0.05 | 20 (5.2) | 6 (4.7) | >0.05 | 3 (5.3) | 1 (5.3) | >0.05 |
| Diarrhea | 55 (5.2) | 9 (3.8) | >0.05 | 17 (4.5) | 5 (3.9) | >0.05 | 3 (5.3) | 2 (10.5) | >0.05 |
| Constipation | 380 (40.9) | 82 (34.9) | >0.05 | 121 (31.8) | 40 (31.0) | >0.05 | 11 (19.3) | 3 (15.8) | >0.05 |
| Rash | 58 (5.5) | 10 (4.3) | >0.05 | 19 (5.0) | 7 (5.4) | >0.05 | 3 (5.3) | 1 (5.3) | >0.05 |
| Weight loss (≥3 kg) | 77 (7.3) | 23 (9.8) | >0.05 | 15 (3.9) | 5 (3.9) | >0.05 | 12 (21.1) | 4 (21.1) | >0.05 |
| Bev-associated | |||||||||
| Hypertension | 1 (0.1) | 2 (0.9) | 0 | 1 (0.8) | 0 | 1 (5.3) | |||
| Proteinuria | 1 (0.1) | 7 (3.0) | 0 | 4 (3.1) | 0 | 2 (10.5) | |||
| Hemoptysis | 0 | 1 (0.4) | 0 | 0 | 0 | 0 | |||
| Epistaxis | 0 | 3 (1.3) | 0 | 1 (0.8) | 0 | 0 | |||
Abbreviations: Bev, bevacizumab; F, first-line treatment; S, second-line treatment; M, maintenance treatment; A, patients who were treated with chemotherapy without bevacizumab; B, patients who were treated with chemotherapy with bevacizumab.